Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) saw a significant decrease in short interest during the month of May. As of May 30th, there was short interest totalling 8,284,614 shares, a decrease of 15.5% from the May 15th total of 9,799,100 shares. Several analysts have recently commented on the stock. Analysts at Roth Capital downgraded shares of Chelsea Therapeutics International from a “buy” rating to a “neutral” … Continue reading Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Wall Street Hot Runners: Molycorp Inc (NYSE:MCP), NQ Mobile (NYSE:NQ), IAMGOLD (NYSE:IAG), Magnum Hunter Resources (NYSE:MHR), Chelsea Therapeutics (NASDAQ:CHTP)

Molycorp Inc (NYSE:MCP) is said to have been downgraded to Underweight from Neutral by JPMorgan financial analysts. The JPMorgan bank downgraded Molycorp Inc (NYSE:MCP) to Underweight as soon as the company reported its Q1 results, stating that Molycorp will look for another capital raise likely this year. Molycorp Inc (NYSE:MCP) stock performance was 1.45% in last session and finished the day at $2.80. Traded volume … Continue reading Wall Street Hot Runners: Molycorp Inc (NYSE:MCP), NQ Mobile (NYSE:NQ), IAMGOLD (NYSE:IAG), Magnum Hunter Resources (NYSE:MHR), Chelsea Therapeutics (NASDAQ:CHTP)

Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

MannKind Corporation (NASDAQ:MNKD) loss of 14 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate by a penny but narrower than the year-ago loss by a penny. MannKind Corporation (NASDAQ:MNKD) did not generate any revenue in the first quarter of 2014, as in the year-ago quarter. Research and development (R&D) expenses remained flat at $26.2 million in the … Continue reading Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)